Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of AZD8630 in Healthy Adults and Adults With Asthma
NCT05110976Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2021
- Primary completion
- Aug 2023
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of azd8630 in asthma, sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events, Time to reach maximum observed concentration (tmax) of AZD8630 (IV cohort) and 2 more. Started Dec 2021; status: completed.
02
Drugs
azd8630
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05110976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110976.